National Cancer Institute / Institut Kanser Negara
Putrajaya 62250
4 studies enrolling now · 4 studies all time
What they study most
Advanced Breast Cancer, Advanced Solid Tumor, Advanced Solid Tumors, HER2-negative Breast Cancer, HR+/HER2- Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Ovarian Cancer
Studies at this site
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — Recruiting now
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease — Recruiting now
- A Study of BG-C477 in Participants With Advanced Solid Tumors — Recruiting now
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) — Recruiting now